Interestingly, SNORD50A binds and inhibits the oncogene KRAS, with depletion of SNORD50A causing activation of the MAPK cascade,9 which is involved in tumour resistance to therapy,10 suggesting a potential role in neo‐tx resistance in RC. Here, CASP4 is linked to neoplasm.